Latest Ratios: P/E Ratio -64.3x · EV/EBITDA 28.0x · ROE -17.1%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.4B | $6.9B | $9.1B | $6.3B | $8.2B | $16.9B | $15.6B | $9.0B | $6.0B | $4.7B | $3.6B |
| Enterprise Value | $9.8B | $7.3B | $9.8B | $7.1B | $9.0B | $16.2B | $15.0B | $8.5B | $5.5B | $4.4B | $3.3B |
| P/E Ratio → | -64.27 | — | — | 77.62 | 56.90 | 73.56 | 64.83 | 45.95 | 31.12 | 38.03 | 11.52 |
| P/S Ratio | 6.17 | 4.52 | 4.35 | 3.10 | 4.01 | 13.63 | 13.62 | 9.62 | 7.01 | 6.00 | 5.03 |
| P/B Ratio | 13.52 | 9.57 | 8.66 | 4.65 | 6.10 | 10.89 | 11.07 | 7.73 | 6.21 | 6.54 | 6.40 |
| P/FCF | 47.64 | 34.91 | 62.72 | 990.79 | — | 73.52 | 118.72 | 60.51 | 27.75 | 417.64 | 9.13 |
| P/OCF | 43.38 | 31.79 | 46.40 | 67.39 | 277.78 | 63.83 | 73.78 | 40.72 | 25.12 | 81.54 | 8.60 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.79 | 4.67 | 3.49 | 4.42 | 13.05 | 13.09 | 9.04 | 6.37 | 5.60 | 4.60 |
| EV / EBITDA | 27.96 | 20.80 | — | 30.44 | 25.98 | 51.94 | 52.50 | 34.65 | 23.84 | 21.70 | 7.24 |
| EV / EBIT | 31.43 | 23.91 | — | 51.65 | 41.04 | 58.88 | 56.70 | 36.15 | 25.48 | 23.72 | 19.76 |
| EV / FCF | — | 36.97 | 67.32 | 1116.88 | — | 70.42 | 114.09 | 56.84 | 25.20 | 389.85 | 8.36 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.9% | 61.9% | 48.0% | 49.0% | 52.0% | 65.2% | 65.0% | 67.1% | 67.0% | 66.1% | 67.1% |
| Operating Margin | 20.5% | 20.5% | -12.7% | 6.7% | 10.3% | 22.3% | 22.4% | 23.6% | 24.2% | 23.3% | 61.2% |
| Net Profit Margin | -9.9% | -9.9% | -14.6% | 4.0% | 7.0% | 18.5% | 21.0% | 20.9% | 22.5% | 16.7% | 42.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -17.1% | -17.1% | -25.2% | 6.0% | 9.9% | 15.5% | 18.7% | 18.4% | 22.9% | 20.5% | 71.9% |
| ROA | -7.0% | -7.0% | -10.8% | 2.6% | 5.6% | 12.8% | 15.5% | 15.4% | 18.8% | 15.3% | 42.3% |
| ROIC | 16.5% | 16.5% | -10.3% | 4.7% | 10.5% | 25.3% | 27.0% | 32.0% | 37.8% | 41.6% | 112.2% |
| ROCE | 18.8% | 18.8% | -11.9% | 5.4% | 10.0% | 17.8% | 18.9% | 19.8% | 23.6% | 27.1% | 81.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.78 | 0.78 | 0.80 | 0.71 | 0.77 | 0.02 | 0.02 | 0.02 | — | — | 0.00 |
| Debt / EBITDA | 1.59 | 1.59 | — | 4.13 | 2.97 | 0.11 | 0.12 | 0.08 | — | — | 0.00 |
| Net Debt / Equity | — | 0.56 | 0.64 | 0.59 | 0.62 | -0.46 | -0.43 | -0.47 | -0.57 | -0.44 | -0.55 |
| Net Debt / EBITDA | 1.16 | 1.16 | — | 3.44 | 2.39 | -2.29 | -2.13 | -2.24 | -2.41 | -1.55 | -0.68 |
| Debt / FCF | — | 2.06 | 4.60 | 126.09 | — | -3.10 | -4.63 | -3.67 | -2.55 | -27.79 | -0.78 |
| Interest Coverage | 9.21 | 9.21 | -6.00 | 2.75 | 8.53 | 915.67 | 781.07 | 714.92 | 303.80 | 275.04 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.49 | 2.49 | 1.98 | 2.18 | 2.08 | 4.63 | 4.71 | 5.78 | 5.35 | 3.69 | 2.30 |
| Quick Ratio | 1.47 | 1.47 | 1.24 | 1.22 | 1.28 | 3.87 | 3.79 | 5.11 | 4.71 | 3.08 | 1.97 |
| Cash Ratio | 0.41 | 0.41 | 0.29 | 0.29 | 0.32 | 2.78 | 2.74 | 3.99 | 3.74 | 2.08 | 1.39 |
| Asset Turnover | — | 0.90 | 0.80 | 0.67 | 0.63 | 0.66 | 0.67 | 0.67 | 0.74 | 0.87 | 0.87 |
| Inventory Turnover | 1.53 | 1.53 | 2.37 | 1.92 | 1.95 | 2.14 | 1.86 | 2.66 | 2.99 | 2.91 | 3.23 |
| Days Sales Outstanding | — | 87.63 | 85.27 | 75.03 | 90.56 | 72.07 | 57.89 | 64.93 | 51.21 | 62.48 | 56.09 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 1.3% | 1.8% | 1.4% | 1.5% | 2.2% | 3.2% | 2.6% | 8.7% |
| FCF Yield | 2.1% | 2.9% | 1.6% | 0.1% | — | 1.4% | 0.8% | 1.7% | 3.6% | 0.2% | 10.9% |
| Buyback Yield | 3.9% | 5.3% | 0.0% | 0.0% | 4.9% | 0.8% | 0.7% | 0.4% | 0.3% | 1.4% | 1.9% |
| Total Shareholder Yield | 3.9% | 5.3% | 0.0% | 0.0% | 4.9% | 0.8% | 0.7% | 0.4% | 0.3% | 1.4% | 1.9% |
| Shares Outstanding | — | $54M | $53M | $54M | $55M | $58M | $58M | $57M | $56M | $56M | $53M |
Consumer segment integration volatility
As reported in recent financial filings, Masimo's forward P/E of 32.73 and negative TTM P/E suggest the market is struggling to reconcile the company's core medical technology growth potential with the significant earnings drag introduced by its recent expansion into the consumer audio electronics market.
The current valuation appears to reflect a conglomerate discount, as investors remain uncertain whether the consumer segment will eventually provide a synergistic 'hospital-to-home' platform or remain a permanent margin dilutive burden. Given the volatility in earnings, the forward P/E multiple may be an unreliable indicator of future performance, warranting a closer look at normalized cash flow multiples instead.
Based on the company's reported figures, ROIC has remained in the low single digits, peaking at 5.7% in 2025Q4, which indicates that Masimo is currently struggling to generate returns on invested capital that exceed its likely cost of capital during this period of strategic transition.
The persistent gap between historical performance and current ROIC levels suggests that the capital-intensive nature of the Sound United acquisition has significantly impaired the company's ability to compound value efficiently. Investors should monitor whether future divestitures or operational improvements can restore ROIC to levels more consistent with its high-margin medical device peers.
According to quarterly data, the cash conversion cycle has remained elevated, reaching 249 days in 2026Q1, which reflects significant inefficiencies in inventory management and a potential buildup of slow-moving consumer audio stock compared to the company's historical clinical monitoring business model.
The dramatic increase in days inventory outstanding, which reached 232 days in the most recent quarter, suggests that the company is carrying excessive inventory levels that tie up liquidity. This trend warrants further investigation into whether the current inventory management practices are sustainable or if they indicate a structural mismatch between production and consumer demand.
As reported in recent balance sheet filings, Masimo maintains a current ratio of 2.68 as of 2026Q1, providing a stable liquidity buffer that appears adequate to cover short-term obligations despite the inherent volatility in the company's working capital and cash-generating cycles.
While the current ratio remains healthy, the reliance on inventory to support this liquidity position may be risky if the consumer audio segment continues to face demand headwinds. The company's ability to maintain this liquidity while navigating activist investor pressure suggests that the balance sheet remains a defensive strength rather than a source of immediate financial distress.
The price-to-earnings ratio is frequently misapplied to Masimo, as the metric is heavily distorted by non-recurring legal expenses and acquisition-related amortization that do not reflect the underlying cash-generating power of the company's core medical technology business.
Analysts should instead focus on EV/EBITDA or free cash flow yield to better understand the company's operational performance, as these metrics strip away the noise of non-operating charges. Relying on P/E in the current environment may lead to an overly pessimistic view of the company's valuation, as it fails to account for the potential for margin expansion once the consumer segment is fully integrated or divested.
Includes 30+ ratios · 23 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MASI stock.
Masimo Corporation's current P/E ratio is -64.3x. The historical average is 40.8x.
Masimo Corporation's current EV/EBITDA is 28.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 23.7x.
Masimo Corporation's return on equity (ROE) is -17.1%. The historical average is 25.0%.
Based on historical data, Masimo Corporation is trading at a P/E of -64.3x. Compare with industry peers and growth rates for a complete picture.
Masimo Corporation has 61.9% gross margin and 20.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Masimo Corporation's Debt/EBITDA ratio is 1.6x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.